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A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma,
morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma
Aims: Fumarate hydratase (FH)-deficient renal cell
carcinoma (RCC) is a high-grade, aggressive tubu-
lopapillary carcinoma, arising predominantly in the
setting of the hereditary leiomyomatosis–RCC syn-
drome of familial uterocutaneous leiomyomatosis and
deficiency of FH. In contrast, succinate dehydroge-
nase (SDH)-deficient RCC is a lower-grade oncocytic
carcinoma with cytoplasmic flocculence/vacuolation
and inclusions, arising mostly in individuals harbour-
ing germline mutations of subunit B of the SDH com-
plex (SDHB). Herein we aim to report the
clinicopathologic features of a novel form of FH-defi-
cient RCC showing a low grade oncocytic morphol-
ogy, reminiscent of SDH-deficient RCC.
Methods and results: These distinctive, low-grade
oncocytic neoplasms, with solid, nested and focally
tubular architecture (2–90 mm), arose in four males
(aged 11–41 years). Uniform cytology of polygonal
cells, with flocculent, vacuolated eosinophilic cyto-
plasm with scattered inclusions, fine chromatin, and
inconspicuous nucleoli, was apparent. Despite these
features suggestive of SDH-deficient RCC, each
tumour was confirmed as an FH-deficient carcinoma
with retained SDHB expression. One case showed a
synchronous, anatomically separate, typical high-
grade FH-deficient RCC; one other showed such a
tumour at nephrectomy 4 years later. No progression
has been noted at 3 and 7 years in the cases with
only the SDH-like lesions; the two cases with sepa-
rate, typical FH-deficient RCCs progressed.
Conclusions: In summary, we characterize a novel
oncocytic type of FH-deficient RCC with a striking
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resemblance to SDH-deficient RCC, posing a diagnos-
tic challenge and raising concerns about sampling
and multifocality for syndrome-associated cases under
surveillance protocols.
Keywords: fumarate hydratase-deficient renal cell carcinoma, hereditary leiomyomatosis–renal cell carcinoma
syndrome, oncocytic carcinoma, renal cell carcinoma, succinate dehydrogenase-deficient renal cell carcinoma
Introduction
Recent series1,2 have shed much light on the clinico-
pathological features of succinate dehydrogenase
(SDH)-deficient renal cell carcinoma (RCC).3,4 Pro-
ceeding from the initial observation of kidney tumours
in kindreds with germline SDHB mutations and a pre-
disposition to develop epithelioid gastrointestinal stro-
mal tumours and multiple pheochromocytomas and
paragangliomas,5 greater experience suggests that
these RCCs are morphologically distinctive,4 are
under-recognized but rare, arise with a slight male
predominance in middle-aged adults, and are fre-
quently bilateral.1,2 The morphology is quite charac-
teristic, with tumours composed of small nests and
sheets of oncocytic polygonal cells, unencapsulated,
and sometimes entrapping peripheral benign tubules.
Cytologically, they show vacuolated pink cytoplasm
and variably prominent, pale eosinophilic inclusions,
thought to represent dysfunctional mitochondria.6
The nuclear features are usually low-grade and mono-
tonous, with what we have called a neuroendocrine-
like chromatin pattern.2 A subset of cases, however,
have shown sarcomatoid transformation with overt
nuclear atypia and an aggressive course. Although
most SDH-deficient RCCs that have been tested have
been shown to harbour SDHB mutations, scattered
reports have identified SDHA and SDHC mutations as
well.7–9 In any case, to assist in their recognition,
SDHB immunohistochemistry (IHC) has been used for
the detection of tumours with SDH subunit mutations
based on consistent loss of SDHB expression by IHC,
whether there is SDHA, SDHB, SDHC or SDHD muta-
tion, owing to mitochondrial complex II instability.3
In contrast, hereditary leiomyomatosis–RCC
(HLRCC) syndrome represents another RCC syndrome,
related to germline mutation of the fumarate hydra-
tase (FH) gene, consisting of highly penetrant cuta-
neous (>90% of males and females) and uterine
(~70% of females) leiomyomatosis with less prevalent
(10–30%)10–12 ‘type 2 papillary’ RCC13 arising in
both males and females over a diverse age range.
Adrenocortical adenomas have been reported in ~10%
of affected subjects.14 The RCCs arising in HLRCC
show a much more variable, high-grade morphology,
including papillary, tubulopapillary, cribriform, cystic
and infiltrative collecting-duct like patterns.15,16
Prospective recognition of these tumours is empha-
sized, owing to their remarkable aggression, for which
IHC for FH (lost in most cases with mutations17) and
for aberrant succination of nuclear and cytoplasmic
proteins [2-succinylcysteine (2SC16)] has been used.
Although most cases are thought to occur with germ-
line rather than somatic FH mutations,18 recent data
have identified apparently somatic mutations in spo-
radic uterine leiomyomas19 and even high-grade pap-
illary RCCs.20 In any case, a great many cases
showing FH deficiency by IHC do not show signs of
this syndrome. For this reason, we have recently pro-
posed21 a term, ‘FH-deficient RCC’, for provisional use,
with recommendation of genetic consultation, in mor-
phologically and immunohistochemically suggestive
cases without apparent syndromic features and
unavailable genotyping.17,22
In a recent interinstitutional review of FH-deficient
RCCs,22 we noted several morphological outliers. On
the basis of prior experience with SDH-deficient RCC,2
we noted tumours with low-grade oncocytic morphol-
ogy, suggestive of SDH deficiency, among cases with
clinical, morphological, immunohistochemical or
molecular evidence suggestive of FH deficiency. Care-
ful review of published cases of HLRCC identified
another case with such morphology,23 which we also
reviewed. Intrigued by the morphological overlap of
these carcinomas across syndromes defined by dis-
parate classic phenotypes but shared metabolic alter-
ations, we present the findings herein.
Marerials and methods
In accordance with the ethical principles of the Decla-
ration of Helsinki, under Institutional Review Board
(IRB)-approved protocols (VCU IRB no.
HM20002545, valid to 26 April 2017; CSMC IRB
no. Pro00027348; valid to 31 January 2018), grant-
ing waivers of consent, cases of RCC arising in the
setting of known or suspected HLRCC were identified
retrospectively from the files of the authors. All sec-
tions of every case were obtained and reviewed, and
deidentified clinicopathological data were collected.
One case has been reported previously by Alrashdi
et al.,23 and this was also re-reviewed with extended
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 42–52.
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follow-up. Routine IHC, with protocols and evaluation
as reported previously for FH22 and 2SC,16 and SDHB
and SDHA,2 was employed. For one case, multiplexed
polymerase chain reaction-based next-generation
sequencing (NGS) of tumour genomic DNA was per-
formed with the Ion Ampliseq Comprehensive Cancer
Panel targeting 409 cancer-related genes, including
FH (and SDHB), with a validation and analysis pipe-
line, and copy number alteration detection as previ-
ously reported,24–26 with cutoffs for variant detection
exactly as previously reported.22
Results
C L I N I C O P A T H O L O G I C A L F E A T U R E S
Table 1 shows the clinicopathological findings per
case. The tumours arose in four males aged
11–41 years. Reasons for presentation included left
back and abdominal pain (Case 1), imaging findings
performed under syndromal surveillance (Case 2),
abdominal pain and anaemia with a history of poly-
cystic kidneys by imaging (Case 3), and incidental
enlarged kidney on magnetic resonance imaging
(Case 4). The oncocytic tumours were multifocal (Fig-
ure 1A) in two cases (Cases 1 and 3) and unifocal in
two cases (Cases 2 and 4). Two cases (Cases 3 and 4)
showed separate (one anatomically distant from the
oncocytic tumour; one presenting 4 years later at
completion nephrectomy) high-grade FH-deficient
RCCs. Two cases provided strong evidence of HLRCC,
including concurrent multiple cutaneous leiomy-
omata (Case 1), and germline mutation-confirmed
HLRCC (Case 2). Case 3 also had a suggestive history,
including a personal history of a first-degree relative
having succumbed to metastatic RCC, and a personal
history of ‘multicystic kidneys’ by imaging. No data
are available regarding HLRCC-associated signs for
Case 4. In terms of clinical outcome, the two cases
with only low-grade oncocytic carcinomas are free of
disease at nearly 3 years and >7 years post-nephrect-
omy. The two cases with separate high-grade
tumours showed progression, at presentation in Case
3 (liver metastasis showing morphology of the high-
grade tumour at frozen section) and at 3 months
after completion nephrectomy (although after 4 years
had elapsed without progression since the partial
nephrectomy with the oncocytic RCC) in Case 4.
The specimens evaluated were three radical
nephrectomies and one partial nephrectomy. The
nephrectomy of Case 1 harboured an ipsilateral
adrenocortical adenoma (27 mm) (Figure 1B),
whereas cutaneous biopsies performed concurrently
with nephrectomy for suspected metastasis (Fig-
ure 1C) proved to be cutaneous, pilar-type leiomy-
omatosis (Figure 1D). The tumours were described as
yellow or tan (Figure 2A), and measured, on gross
examination, from 2 mm up to 90 mm. In three
cases, these were seen adjacent to variable back-
ground cystic change (Figures 3A, 4A,C, and 5A). In
each case, the tumours were grossly unencapsulated
but appeared not to have infiltrated the adjacent
structures, bulging but confined to the kidney.
H I S T O L O G I C A L F E A T U R E S
Morphologically, these tumours showed low-grade
oncocytic morphology, with confluent solid or nested
confluent growth and prominent nodularity, closely
juxtaposed to the adjacent renal parenchyma (Fig-
ures 2B and 3A). At higher power, the architecture
showed a mixed pattern, in some areas with tubular
morphology (Figures 2C,D and 3B,C), sometimes
dilated to impart a microcystic appearance with pink
luminal contents (Figure 2C). One nodule showed
prominent stromal oedema with dispersed tubular
aggregates of cells (Figure 2D); in other foci, tubular
growth was more packed (inset). Cytologically, con-
sistent oncocytic features were seen, with tumours
being composed of polygonal cells with eosinophilic
cytoplasm with scattered vacuoles and predominantly
round, regular nuclei (Figures 2E, 3C, 4B,D, and 5B).
The chromatin was finely granular; many examples
showed micronucleoli that were not prominent at
910 [International Society of Urological Pathology
(ISUP) grade 2]. Numerous stromal mast cells were
apparent in many areas (Figure 2E). All cases showed
variable cytoplasmic flocculence or vacuolation; in
three cases (Cases 2–4), cytoplasmic inclusions of
pink hyaline material reminiscent of those that have
been described in SDH-deficient RCC were readily
identifiable (Figures 3C and 5B). No coagulative
tumour cell necrosis was identified in any of these
tumours, and nor were features of vascular invasion
present, including in the multifocal cases, which were
interpreted histologically as independent neoplastic
foci.
Two cases (Cases 3 and 4) showed separate RCCs
with features that have been associated with typical
high-grade FH-deficient RCC. Case 3 showed a
35-mm tumour, in the upper pole of the kidney, dis-
tant from the oncocytic tumours, with prominent
tubulocystic morphology and poorly differentiated,
solid areas with a cribriform and syncytial appear-
ance (Figure 4E,F); a metastatic liver lesion with this
morphology was present at nephrectomy. In Case 4,
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 42–52.
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a completion nephrectomy was performed 4 years
after the partial nephrectomy (which had shown the
low-grade oncocytic RCC), and a 50-mm high-grade
RCC with tubulocystic and infiltrative collecting-duct
carcinoma-like areas was identified, invasive of renal
sinus adipose (Figure 5C). In both of these cases the
cytology of the high-grade tumours was high-grade
(ISUP grade 3–4), with a syncytial appearance and
prominent, viral inclusion-like nucleoli with perinu-
clear halos (Figure 5D).
I M M U N O H I S T O C H E M I C A L A N D M O L E C U L A R
F E A T U R E S
In all four cases, the oncocytic tumours showed
strong/diffuse retained expression of both SDHB and
SDHA, with loss of expression of FH and induction of
strong nucleocytoplasmic 2SC positivity (Figures 2F,
3D, and 5B). PAX8 expression was diffuse in all of
the oncocytic tumours (not pictured), with variable,
patchy expression of pancytokeratin AE1/AE3 and
the oncocytic renal neoplasia-associated marker kid-
ney-specific cadherin (Ksp-cadherin), as shown in
Table 2. It is of note that the cutaneous leiomyoma
seen in Case 1 also showed SDHB/SDHA positivity
with loss of FH (Figure 1D), whereas the separate
high-grade carcinomas seen in Cases 3 and 4 were
both FH-deficient. In Case 3, NGS was performed on
the low-grade oncocytic RCC, and identified homozy-
gous FH frameshift mutations (p.K80 fs). This muta-
tion was identical to the homozygous FH mutations
observed in the anatomically separate high-grade
FH-deficient RCC.22 Nevertheless, on comparison of
genome-wide copy number alterations between these
two separate carcinomas, the oncocytic tumour
lacked the copy number gains (chromosome 8q) and
losses (chromosome 18) seen in the high-grade FH-
deficient carcinoma (Figure 4H). Consistent with the
IHC findings, no SDHB mutations were identified.
Discussion
Recent years have seen the recognition of distinctive
morphological features of subtypes of RCC associated
with genetic syndromes, including the SDH-deficient
A B
C D
Figure 1. Clinical findings at presentation for Case 1 included enhancing, multinodular, focally calcified left kidney masses arising in the
upper, interpolar and lower poles of the kidney (A). An enlarged ipsilateral adrenal gland excised at nephrectomy was confirmed to be an
adrenocortical adenoma (B). Multiple nodular cutaneous tumours seen on preoperative imaging and interpreted as suspicious for metastasis
(C, arrows) proved to be cutaneous, pilar-type leiomyomata (D). Fumarate hydratase immunostaining was negative in this tumour (inset:
see internal control positive endothelium), a pattern that has been interpreted as highly suspicious for hereditary leiomyomatosis–renal cell
carcinoma-associated cutaneous leiomyomatosis.39 [Colour figure can be viewed at wileyonlinelibrary.com]
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 42–52.
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RCCs associated with familial paraganglioma/
pheochromocytoma syndromes3,4 and the FH-defi-
cient RCCs associated with HLRCC syndrome.15 From
the standpoint of the diagnostic pathologist, recogni-
tion of these RCC subtypes is of the utmost impor-
tance, owing to the need to risk-stratify individual
tumours on the basis of increasing published experi-
ence1,2,17,22 and to recommend genetic counselling
and testing for patients and their families.
With regard to the present cases, we first note that
the evidence available suggests that three of these
cases represent HLRCC, although proof of germline
mutation of FH (observation of the same constitu-
tional FH mutation in two separate generations) is
unavailable except for the second case, which arose
in a patient from a well-characterized HLRCC fam-
ily.23 The first case, arising in an individual showing
multiple, histologically confirmed cutaneous
A B
C D
E F
Figure 2. The kidney tumour resected in Case 1 showed grossly a partly exophytic multinodular mass with striking yellow gross morphology
(A). At low power, a solid appearance was imparted by a tumour composed of densely packed nests of cells with eosinophilic cytoplasm (B).
At intermediate power, scattered foci with a more tubular and more microcystic appearance with dense pink luminal contents were noted
(C). Similarly, one of the many tumour nodules had prominent stromal myxoedematous change (D), with occasional hobnail-shaped cells
protruding into the centres of tubules (inset). However, the predominantly solid and nested tumour was composed of cells with oncocytic
morphology, variably flocculent cytoplasm, and nuclei with finely granular chromatin with scattered small nucleoli (E); stromal mast cells
were very prevalent (arrows). Expression of fumarate hydratase as determined by immunohistochemistry was lost (F, note internal control
expression in endothelial cells), whereas expression of 2-succinylcysteine was strongly induced, and SDHA and SDHB expression was
retained (insets: each as indicated). SDH, Succinate dehydrogenase.
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 42–52.
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leiomyomas, and the third case, with the separate
‘type 2 papillary’ RCC or ‘collecting duct carci-
noma’27 before the age of 40 years and with an
affected first-degree relative, would meet the criteria
reported by Menko et al.28 for likely HLRCC. Quite
suggestive of a constitutional mutation, this third
case also had the same homozygous FH mutation
detected in the anatomically separate SDH deficient-
like and typical high-grade FH-deficient RCCs. Nota-
bly, no data regarding a family history of HLRCC or a
personal or family history of uterocutaneous leiomy-
omatosis are available for the fourth case. In light of
recently reported data showing that uterine leiomy-
omata and even FH-mutant RCCs may occur through
somatic mutations,19,20 we can only regard this case
as an FH-deficient RCC.21,22
We acknowledge the wisdom of the opinion held
by some that explicit observation of a germline FH
mutation remains the true gold standard for HLRCC
diagnosis;15,16 in three of our cases, this will remain
impossible (not allowed under the retrospective proto-
cols governing the study). Our inability to retrospec-
tively perform genetic testing for constitutional
changes in FH and SDHB remains the most
important limitation of this study. Moreover, it under-
scores the essential role of the surgical pathologist in
the early recommendation of genetic consultation for
patients with tumours in this morphological and clin-
ical spectrum. Only accumulated, carefully genetically
documented clinical experience will answer the ques-
tion of whether FH-deficient or SDH-deficient RCCs
occur sporadically by somatic mutation at any fre-
quency. Indeed, SDH-deficient paragangliomas29,30
and other lesions with only somatic SDH subunit
mutations31 have been described, making this issue
all the more salient.
With regard to the oncocytic tumours, we do not
argue that these tumours represent perfect mor-
phological phenocopies of the most characteristic
SDH-deficient RCCs. However, in each case, when
encountered after our prior studies of SDH-deficient
RCCs,2 we were sufficiently suspicious that we ordered
SDH-deficient workup (by IHC). Each case showed
oncocytic morphology with stromal mast cells and
areas of distinctive cytoplasmic flocculence and vacuo-
lation, with at least focal inclusion-like formations.
The predominant architectural pattern was solid or
nested, although a tubular or pseudoglandular
A B
C D
Figure 3. Case 2, arising in an 11-year-old male with proven hereditary leiomyomatosis–renal cell carcinoma, showed a dilated cyst, with adja-
cent cellular proliferation (A). At intermediate power (B), the carcinoma was seen to be composed of tubules and nests of oncocytic cells with indis-
tinct nucleoli. At higher power (C), flocculent eosinophilic cytoplasm was readily apparent, as were several examples of large cytoplasmic vacuoles,
containing eosinophilic inclusions (arrows). By immunohistochemistry (D), the tumour lacked expression of fumarate hydratase (note weak reten-
tion in internal control microvasculature) and showed induction of strong nucleocytoplasmic 2-succinylcysteine expression, and retained SDHB
and SDHA expression (insets: as indicated). SDH, Succinate dehydrogenase. [Colour figure can be viewed at wileyonlinelibrary.com]
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 42–52.
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pattern, as reported previously in SDH-deficient RCCs,1
was prominent in areas of two of the cases. Pancytok-
eratin AE1/AE3 was positive in a variable, patchy
manner; Ksp-cadherin was positive in three cases, sim-
ilarly to SDH-deficient RCC,2 as is characteristic of
oncocytic renal neoplasia generally,32 as was PAX8.
Most important, however, was the observation in all
three tumours of consistently retained SDHB expres-
sion in a strong, diffuse manner, reflective of an intact
SDH complex.33 In contrast, FH expression was lost
and 2SC expression was strongly, diffusely induced in
a nucleocytoplasmic manner, a pattern that has pro-
ven, in our experience16,22,34 and that of
others,17,35,36 to be demonstrative of FH mutation and
loss of function. Thus, we interpret the FH-negative/
2SC-positive immunophenotype in each of these
tumours as being confirmatory of their specificity to
FH deficiency and exclusive of their representing an
A B
C D
Figure 5. In the fourth case, a partial nephrectomy was performed, sampling a solid lesion in an enlarged multicystic kidney. A 50-mm solid
nodule was seen (A, arrows) adjacent to a multicystic lesion, composed of nests of oncocytic cells with even chromatin and indistinct nucle-
oli (B). The cytoplasm was variably flocculent, with infrequent vacuoles with eosinophilic inclusion-like bodies (arrow). fumarate hydratase
(FH) expression was lost, whereas strong/diffuse nucleocytoplasmic 2-succinylcysteine expression was identified (insets); SDHA and SDHB
expression was retained (not shown). Although completion nephrectomy was recommended, it was performed 4 years later, showing a
high-grade, infiltrative renal cell carcinoma (RCC) with glandular, solid and tubulocystic growth patterns, invasive of renal sinus adipose
(C). The cytology of this later tumour, which was also FH-deficient (D, inset), was markedly different, with large, variably shaped nuclei with
prominent, inclusion-like nucleoli with perinuclear halos (D), much more in the spectrum described for typical FH-deficient RCCs. SDH,
Succinate dehydrogenase. [Colour figure can be viewed at wileyonlinelibrary.com]
Table 2. Immunohistochemical findings
Case PAX8 SDHB SDHA FH 2SC Ksp-cadherin PanCK
1 Diffuse, nuclear Retained Retained Lost Strong/diffuse, nucleocytoplasmic Diffuse, membranous Patchy, variable
2 Diffuse, nuclear Retained Retained Lost Strong/diffuse, nucleocytoplasmic Negative Patchy, weak
3 Diffuse, nuclear Retained Retained Lost Strong/diffuse, nucleocytoplasmic Diffuse, membranous Patchy, variable
4 Diffuse, nuclear Retained Retained Lost Strong/diffuse, nucleocytoplasmic Focal, membranous Patchy, weak
FH, Fumarate hydratase; Ksp-cadherin, Kidney-specific cadherin; PanCK, Pancytokeratin AE1/AE3; PAX8, Paired-box 8; SDHA, Succinate
dehydrogenase, subunit A; SDHB, Succinate dehydrogenase, subunit B; 2SC, 2-Succinylcysteine.
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aetiologically unrelated epiphenomenon (sporadic-type
carcinomas arising in the polycystic background, for
instance).
In summary, we describe four intriguing cases:
tumours with low-grade oncocytic morphology and
variable cytoplasmic vacuolation and flocculence. On
morphological grounds, these tumours were first
deemed to be quite reminiscent of SDH-deficient RCC.
However, immunophenotypic workup points to their
representing a novel morphological type of FH-defi-
cient carcinoma, including loss of FH expression,
induction of strong, diffuse nucleocytoplasmic 2SC
immunostaining, and retained expression of SDHB, to
say nothing of the clinical features that are quite sug-
gestive of (or confirmed) HLRCC in three of them. We
speculate that these tumours represent yet another
example of an emerging phenomenon of phenotypic
‘crossover lesions’ between FH-deficient and SDH-defi-
cient syndromes, analogous to recently described
paragangliomas occurring in the setting of germline
FH mutation.35,37,38
Two of these novel cases also raise the possibility
that, when not associated with a high-grade FH-defi-
cient RCC, this oncocytic tumour type could be asso-
ciated with a more favourable outcome. High-grade
FH-deficient RCCs have been associated with progres-
sion and/or death from disease in 30–80% of
cases.15,17,22 Our experience with these low-grade
oncocytic tumours emphasizes the importance of
morphological context for interpreting IHC and
molecular findings. Despite the shared ‘FH-deficient
RCC’ status of both the low-grade oncocytic tumours
and typical high-grade FH-deficient RCCs, such a
high-risk label would have been inappropriate for the
low-grade tumours, given that progression was only
seen in cases with a separate high-grade tumour. Cer-
tainly, much more study is needed, and, prospec-
tively, we recommend careful inquiry regarding the
nature of any syndromal signs and the use of SDHB,
SDHA and FH IHC, as well as genetics referral, for
concerning cases. Moreover, given the presence of
anatomically (or chronologically) separate, disparate
lesions of very different grades, we recommend care-
ful correlation between imaging, sampling and
histopathology for surveillance or sampling protocols.
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